{"prompt": "['MC1575', '71', 'Amendment 2', 'Recommended Hypertension Monitoring and Management for non-', 'secretory tumors (BP in mmHg)', 'Grade', 'Antihypertensive', 'Blood Pressure', 'Lenvatinib', '(CTCAE v4)', 'Therapy', 'Monitoring', 'Dose Modification', 'hypertensives in Step 2;', 'increase dose of this drug', 'as described in Step 1', 'Step 4) If BP still not', 'controlled, discontinue', 'lenvatinib until BP', 'controlled, then resume', 'NOTE: Stopping or', 'reducing the dose of', 'lenvatinib is expected to', 'cause a decrease in BP.', 'The treating physician', 'should monitor the', 'subject for hypotension', 'and adjust the number', 'and dose of anti-', 'hypertensive medic-', 'ation(s) accordingly', 'Persistent Grade 3', 'HOLD lenvatinib until', 'BP should be', 'HOLD lenvatinib', 'Severe', 'systolic BP <159 and', 'monitored as', 'until systolic BP', 'Systolic >160', 'diastolic BP <99', 'recommended by the', '<159 and diastolic', 'Diastolic >100', 'treating physician', 'BP 99. After this,', 'BP management is', 'unless the subject is', 'lenvatinib may be re-', 'Protocol-specific', 'identical to that for', 'symptomatic with', 'administered. If BP is', 'guidance supersedes', 'Grade 2 (see Steps 1-4', 'systolic BP >180 or', 'still Grade 2, manage', 'any other management', 'above) with 2 major', 'diastolic BP>110 in', 'as described above', 'guidelines, including', 'exceptions:', 'which case,', 'for Grade 2', 'CTCAE v4', '1) If systolic BP >180 or', 'monitoring should', 'hypertension.', 'diastolic BP >110 and', 'be intensive', 'the subject is', 'In most', 'symptomatic: optimal', 'circumstances, if BP', 'management with', 'cannot be controlled', 'intensive IV support in', 'after an optimal trial', 'ICU; STOP lenvatinib', 'of antihypertensive', 'and notify hospital staff', 'medications, consider', 'that stopping drug may', 'either 1 dose', 'result in a decrease in', 'reduction of', 'BP', 'lenvatinib when', 'and', 'systolic BP <159 and', '2) If svstolic BP >180 or', 'diastolic BP 99 or', 'diastolic BP >110 and', 'stopping lenvatinib.', 'the subject is', 'asymptomatic,', 'HOWEVER,', 'consideration to', 'If the subject', 'initiation of 2 new', 'requires', 'antihypertensives', 'hospitalization for', 'together should be given', 'management of', 'in step 1 (and dose', 'symptomatic', 'escalated appropriately', 'systolic BP >180 or', 'as in step 1).', 'diastolic BP >110,', 'Protocol Version Date:16Aug2018']['MC1575', '72', 'Amendment 2', 'Recommended Hypertension Monitoring and Management for non-', 'secretory tumors (BP in mmHg)', 'Grade', 'Antihypertensive', 'Blood Pressure', 'Lenvatinib', '(CTCAE v4)', 'Therapy', 'Monitoring', 'Dose Modification', 'permanently', 'NOTE: Stopping or', 'discontinue', 'reducing the dose of', 'lenvatinib or if BP is', 'lenvatinib is expected to', 'controlled to systolic', 'cause a decrease in BP.', 'BP <159 and', 'The treating physician', 'diastolic BP 99,', 'should monitor the', 'consider re-starting', 'subject for hypotension', 'lenvatinib at 1 lower', 'and adjust the number', 'dose level after', 'and dose of', 'consultation with the', 'antihypertensive', 'Principal Investigator', 'medication(s) accordingly', 'Grade 4', 'Optimal management', 'Intensive', 'Permanently', 'Life-threatening', 'with intensive IV', 'discontinue', 'consequences of', 'support in ICU; STOP', 'lenvatinib or if', 'hypertension', 'lenvatinib and notify', 'systolic BP <159 and', 'hospital staff that', 'diastolic BP 99,', 'stopping lenvatinib may', 'consider restarting', 'result in a decrease in', 'lenvatinib at 1 lower', 'BP', 'dose level after', 'consultation with the', 'Principal Investigator', 'Abbreviations: Dihydropyridine calcium-channel blockers (DHP-CCB), selective beta blockers (BB),', 'Angiotensin Converting Enzyme Inhibitors (ACEI), Angiotensin II Receptor Blockers (ARB), alpha beta', 'blocker (ABB)', 'See table below for suggested antihypertensive medications by class', 'If subjects require a delay of >>2 weeks for management of hypertension, discontinue protocol therapy', '24-48 hours should elapse between modifications of antihypertensive therapy', 'Hypertension should be graded using CTCAE v4', '*NOTE: For the purposes of dosage reductions related to hypertension, persistent', 'hypertension is defined as blood pressure elevations that meet the grading criteria on', 'at least 2 separate measurements 7 days or more apart. (For the purpose of AE', 'grading standard CTCAE will be utilized.)', 'In some instances of treatment for hypertension, a lower dose of the medication may be', 'sufficient to provide the required antihypertensive control. In other instances, the standard', 'dose of such a medication may be associated with AEs because of increased exposure.', 'Alternatively, the investigator may choose to replace the medication with another in the', 'same pharmacologic class that is less likely to interact with lenvatinib. If such a medication', 'is discontinued and replaced, the transition period should occur no less than 7 days prior to', 'the first dose of lenvatinib. Based on prior clinical experience with lenvatinib, the use of', 'calcium channel blockers (dihydropyridine category) and ACE inhibitors as first-line and', 'second-line therapy is recommended.', 'Protocol Version Date: :16Aug2018']\n\n###\n\n", "completion": "END"}